Sector Expert: Dan Trang

Stonegate Securities



Recent Quotes

"RVX is set to begin its BETonMACE trial in fall 2015."

— Dan Trang, Stonegate Capital Partners (8/17/15)
more >

"RVX is uniquely positioned to leverage its novel RVX-208 in cardiovascular disease."

— Dan Trang, Stonegate Capital Partners (4/1/15)
more >

"The successful completion of the Phase 3 study is expected to enhance the value of CVM's business."

— Dan Trang, Stonegate Capital Partners (2/11/15)
more >

"CYTX continues its growth story."

— Dan Trang, Stonegate Securities (3/18/14)
more >

"We initiate coverage of FDNH and believe the future is bright for the company."

— Dan Trang, Stonegate Securities (2/12/14)
more >

"Walgreens' procurement of OCLS' Puracyn products is positive."

— Dan Trang, Stonegate Securities (11/25/13)
more >



Due to permission requirements, not all quotes are shown.